MedTrace Logo

Antibodies in Repeated Influenza Vaccination (ARIVA) Study

NCT04059991 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2021-09-28

No results posted yet for this study

Summary

Viruses with high mutation rates, such influenza or HIV, pose a major challenge for vaccine design. The current influenza vaccination strategy of yearly vaccination with adapted strains aims to maximally diversify the antibody immune response to prevent viral escape. There is, however, growing evidence, that repeated vaccination with very similar viral proteins might limit, instead of broaden, diversification and thereby reduce vaccine efficacy.

The ARIVA Study prospectively studies the immunological impact of repeated influenza vaccination on viral variant recognition and antibody responses in healthy subjects cross-sectionally and over three consecutive vaccination seasons.

Conditions

  • Vaccine Response Impaired

Interventions

BIOLOGICAL

Influenza Vaccination

Only subjects vaccinated against influenza will be enrolled. The study itself is observational

Sponsors & Collaborators

  • University of Oslo

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Christoph T Berger, MD · University Hospital Basel, Medical Outpatient Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04059991 on ClinicalTrials.gov